Bharat Biotech

Coordinates: 17°39′55″N 78°36′17″E / 17.6652°N 78.6047°E / 17.6652; 78.6047
Source: Wikipedia, the free encyclopedia.

17°39′55″N 78°36′17″E / 17.6652°N 78.6047°E / 17.6652; 78.6047

Bharat Biotech International Limited
RevenueIncrease 8,148 crore (US$1.0 billion) (FY22)[3]
Increase 2,895 crore (US$360 million) (FY22)[3]
SubsidiariesChiron Behring Vaccines [4]
Websitewww.bharatbiotech.com

Bharat Biotech International Limited (BBIL) is an Indian multinational

pharmaceuticals and healthcare products.[5]

Overview

Bharat Biotech has its manufacturing facility situated at Genome Valley, Hyderabad, India.[5] As of July 2020, the company has over 700 employees[6] and has a presence worldwide.[5]

The company has been responsible for developing an eco-friendly recombinant

Japanese Encephalitis.[14] Bharat Biotech has biosafety level 3 (BSL3) laboratories.[15]

COVID-19 vaccine development

In April 2020, the company announced that they have partnered with US-based company FluGen and

University of Wisconsin-Madison to develop a COVID-19 vaccine.[16][17]

A 5ml vial of Covaxin

In May 2020, Indian Council of Medical Research's (

Indian Council for Medical Research for Phase I and II randomised, double-blind and placebo-controlled clinical trials of vaccine candidate.[25][26]

In September 2020, the company announced that it was going to manufacture the novel chimp-adenovirus, a single dose

BBV154) for COVID-19 being developed in collaboration with the American company Precision virologics[27] and Washington University School of Medicine in St. Louis, Missouri. It is currently undergoing clinical trials.[28][29] On October 12 2021, Bharat Biotech's Covaxin got approved for usage on children between 2 and 18 years of age. [30]

Attempted data theft

In March 2021, Reuters reported that Chinese state-backed cyber-espionage group Red Apollo targeted Bharat Biotech's intellectual property for exfiltration.[31]

See also

References

  1. ^ "WHO prequalifies new rotavirus vaccine". WHO. Archived from the original on 17 July 2020. Retrieved 2 July 2020.
  2. ^ "WHO recommends use of first typhoid conjugate vaccine". WHO. Archived from the original on 7 September 2018. Retrieved 2 July 2020.
  3. ^ a b "Bharat Biotech International Limited: Ratings reaffirmed". ICRA. Retrieved 16 April 2024.
  4. ^ "Bharat Biotech buys Chiron Behring Vaccines from GSK". The Hindu BusinessLine. 15 February 2019. Archived from the original on 31 August 2020. Retrieved 1 July 2020.
  5. ^ a b c "Bharat Biotech International Ltd". www.bloomberg.com. Archived from the original on 16 November 2020. Retrieved 3 July 2020.
  6. ^ "Leading Biotech Vaccine Manufacturers in India - Bharat Biotech". www.bharatbiotech.com. Archived from the original on 5 July 2020. Retrieved 30 June 2020.
  7. ^ "Process for the preparation and purification of recombinant proteins". patents.google.com. US patent No US8956812B2. 23 August 2004. Archived from the original on 9 May 2021. Retrieved 30 June 2020.
  8. PMID 24629994
    .
  9. .
  10. ^ "Bharat Biotech's Zika, Chikungunya vaccines to enter Phase II trials; focus now on private label market". Moneycontrol. Archived from the original on 30 June 2020. Retrieved 30 June 2020.
  11. ^ "CEPI, 치쿤구니아 백신 개발 위해 국제백신연구소-바라트 바이오텍 컨소시엄에 최대 1410만달러 지원". CEPI, 치쿤구니아 백신 개발 위해 국제백신연구소-바라트 바이오텍 컨소시엄에 최대 1410만달러 지원 - 뉴스와이어 (in Korean). 3 June 2020.
  12. ^ "Bharat Biotech gets breakthrough in developing Zika vaccine". The Economic Times. 4 February 2016. Archived from the original on 9 May 2021. Retrieved 30 June 2020.
  13. ^ "CEPI awards up to US$14.1million to consortium of IVI and Bharat Biotech to advance development of Chikungunya vaccine in collaboration with Ind-CEPI – IVI". www.ivi.int. International Vaccine Institute. 3 June 2020. Archived from the original on 24 September 2020. Retrieved 30 June 2020.
  14. PMID 25601942
    .
  15. ^ "Slow off the starting blocks for Bharat Biotech's Covaxin mass production". The New Indian Express. 17 May 2021. Retrieved 4 June 2021.
  16. ^ "UW-Madison, Flugen, Bharat Biotech to develop coroflu, a coronavirus vaccine". Global Health Institute. Archived from the original on 10 February 2021. Retrieved 30 June 2020.
  17. ^ "Bharat Biotech ties up with US varsity for Covid vaccine". Hindustan Times. 20 May 2020. Archived from the original on 3 May 2021. Retrieved 30 June 2020.
  18. ^ "ICMR teams up with Bharat Biotech to develop Covid-19 vaccine". Livemint. 9 May 2020. Archived from the original on 3 May 2021. Retrieved 30 June 2020.
  19. ^ Chakrabarti, Angana (10 May 2020). "India to develop 'fully indigenous' Covid vaccine as ICMR partners with Bharat Biotech". ThePrint. Archived from the original on 3 May 2021. Retrieved 30 June 2020.
  20. ^ "India's First COVID-19 Vaccine Candidate Approved for Human Trials". The New York Times. 29 June 2020. Archived from the original on 2 July 2020. Retrieved 30 June 2020.
  21. ^ "Human trial of India coronavirus vaccine announced". BBC News. 30 June 2020. Archived from the original on 3 May 2021. Retrieved 30 June 2020.
  22. ^ "Bharat Biotech's Covid vaccine 1st in India to get approval for human trials". The Indian Express. 30 June 2020. Archived from the original on 3 May 2021. Retrieved 30 June 2020.
  23. ^ "Covaxin: India's first COVID19 vaccine candidate from Bharat Biotech to begin human trials; check details". The Financial Express. 30 June 2020. Archived from the original on 3 May 2021. Retrieved 30 June 2020.
  24. ^ "Bharat Biotech COVID-19 vaccine: Testing underway at CDL-Kasauli, volunteer enrolment begins". Moneycontrol. Archived from the original on 10 July 2020. Retrieved 10 July 2020.
  25. ^ "Human clinical trials of potential Covid-19 vaccine 'COVAXIN' started at AIIMS". DD News. Prasar Bharati, Ministry of I & B, Government of India. 25 July 2020. Archived from the original on 24 January 2021. Retrieved 7 August 2020.
  26. ^ "Delhi: 30-year-old is first to get dose of trial drug Covaxin". The Indian Express. 25 July 2020. Archived from the original on 16 March 2021. Retrieved 7 August 2020.
  27. ^ "COVID-19 | Office of Technology Management/Tech Transfer | Washington University in St. Louis".
  28. ^ "Bharat Biotech to make a billion doses of an intranasal adenovirus vaccine". The Indian Express. 23 September 2020. Archived from the original on 3 May 2021. Retrieved 23 September 2020.
  29. ^ "Bharat Biotech Partners With US University For Covid Intranasal Vaccine". NDTV.com. Archived from the original on 3 May 2021. Retrieved 23 September 2020.
  30. ^ "COVID-19: Covaxin Vaccine Approved For Children Between 2 to 18". The Live Mirror. 12 October 2021. Retrieved 12 October 2021.
  31. ^ Das, Krishna N. (1 March 2021). "Chinese hackers target Indian vaccine makers SII, Bharat Biotech, says security firm". Reuters. Archived from the original on 3 May 2021. Retrieved 1 March 2021.

External links